NECTIN2

Across TCGA pan-cancer cohorts, NECTIN2 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated NECTIN2 data layer compared with 25 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where higher NECTIN2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated NECTIN2 expression acts as an unfavorable survival marker, although some lineages such as UCEC and BLCA show a favorable association.

KIRC, SARC, and PRAD are the cancer types where NECTIN2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRC	OS	Median	All	0.054	0.881	<.001	48	view →
SARC	DFS	Median	All	0.095	0.632	.002	6	view →
PRAD	DFS	Median	All	0.617	0.886	.035	6	view →
LIHC	OS	Median	All	0.167	0.688	.035	6	view →
SKCM	DFS	Median	III,IV	0.119	0.654	.003	3	view →
UCEC	DFS	Median	All	0.953	0.829	.043	2	view →
BLCA	OS	Median	II,III,IV	1.000	0.702	.043	2	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

NECTIN2–KIRC (OS)

Open the KIRC breakdown →